These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19451604)

  • 1. Is vancomycin obsolete?
    Legendre D
    Am J Health Syst Pharm; 2009 Jun; 66(11):977-8. PubMed ID: 19451604
    [No Abstract]   [Full Text] [Related]  

  • 2. Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence.
    Deresinski S
    Clin Infect Dis; 2007 Jun; 44(12):1543-8. PubMed ID: 17516396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two heterogeneously vancomycin-intermediate clinical isolates of methicillin-sensitive and methicillin-resistant Staphylococcus aureus in a Turkish university hospital: brief report of a surveillance study.
    Torun MM; Bahar H; Demirci M; Altaş K; Bağdatli Y; Kocazeybek B; Kapi M; Hiramatsu K
    Int J Antimicrob Agents; 2005 Dec; 26(6):508-10. PubMed ID: 16256313
    [No Abstract]   [Full Text] [Related]  

  • 4. Intermediate vancomycin resistance in Staphylococcus aureus: a major threat or a minor inconvenience?
    Johnson AP
    J Antimicrob Chemother; 1998 Sep; 42(3):289-91. PubMed ID: 9786466
    [No Abstract]   [Full Text] [Related]  

  • 5. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus.
    Mohr JF; Murray BE
    Clin Infect Dis; 2007 Jun; 44(12):1536-42. PubMed ID: 17516395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.
    Hiramatsu K; Hanaki H; Ino T; Yabuta K; Oguri T; Tenover FC
    J Antimicrob Chemother; 1997 Jul; 40(1):135-6. PubMed ID: 9249217
    [No Abstract]   [Full Text] [Related]  

  • 8. Vancomycin for Staphylococcus aureus therapy of respiratory tract infections: the end of an era?
    Nathwani D; Tillotson GS
    Int J Antimicrob Agents; 2003 Jun; 21(6):521-4. PubMed ID: 12791464
    [No Abstract]   [Full Text] [Related]  

  • 9. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin.
    Price J; Atkinson S; Llewelyn M; Paul J
    Clin Infect Dis; 2009 Apr; 48(7):997-8. PubMed ID: 19260820
    [No Abstract]   [Full Text] [Related]  

  • 10. [Nosocomial methicillin-resistant staphylococci that remain sensitive to non-beta lactam antibiotics].
    Manfredi R; Nanetti A; Morelli S; Valentini R; Ferri M; Calza L; Chiodo F
    Recenti Prog Med; 2003; 94(7-8):344. PubMed ID: 12868245
    [No Abstract]   [Full Text] [Related]  

  • 11. Vancomycin-resistant Staphylococcus aureus.
    Lessing MP; Raftery MJ
    Lancet; 1998 Feb; 351(9102):601-2. PubMed ID: 9492813
    [No Abstract]   [Full Text] [Related]  

  • 12. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.
    Mariani PG; Sader HS; Jones RN
    J Antimicrob Chemother; 2006 Aug; 58(2):481-3. PubMed ID: 16847029
    [No Abstract]   [Full Text] [Related]  

  • 14. New cases of vancomycin-intermediate MRSA infection reported.
    Am J Health Syst Pharm; 1999 Apr; 56(8):705-6. PubMed ID: 10326611
    [No Abstract]   [Full Text] [Related]  

  • 15. Staph with lower vancomycin resistance in US.
    OR Manager; 1997 Oct; 13(10):7. PubMed ID: 10174189
    [No Abstract]   [Full Text] [Related]  

  • 16. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.
    Máiz L; Cantón R; Mir N; Baquero F; Escobar H
    Pediatr Pulmonol; 1998 Oct; 26(4):287-9. PubMed ID: 9811080
    [No Abstract]   [Full Text] [Related]  

  • 17. Update on emerging infections: news from the Centers for Disease Control and Prevention.
    Moran GJ; Mount J
    Ann Emerg Med; 2003 Jan; 41(1):148-51. PubMed ID: 12514697
    [No Abstract]   [Full Text] [Related]  

  • 18. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital.
    Ploy MC; Grélaud C; Martin C; de Lumley L; Denis F
    Lancet; 1998 Apr; 351(9110):1212. PubMed ID: 9643727
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia.
    Sakoulas G; Gold HS; Cohen RA; Venkataraman L; Moellering RC; Eliopoulos GM
    J Antimicrob Chemother; 2006 Apr; 57(4):699-704. PubMed ID: 16464892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
    Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
    N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.